Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -12.97% and Operating profit at -23.72% over the last 5 years
2
The company has declared Positive results for the last 5 consecutive quarters
3
With ROE of 6.30%, it has a very expensive valuation with a 6.16 Price to Book Value
4
Consistent Returns over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 19,324 Million (Large Cap)
98.00
NA
0.58%
-0.74
6.30%
6.16
Revenue and Profits:
Net Sales:
491 Million
(Quarterly Results - Jun 2025)
Net Profit:
96 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-27.28%
0%
-27.28%
6 Months
-1.22%
0%
-1.22%
1 Year
15.69%
0%
15.69%
2 Years
66.15%
0%
66.15%
3 Years
92.87%
0%
92.87%
4 Years
46.94%
0%
46.94%
5 Years
12.04%
0%
12.04%
Beijing Aosaikang Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-12.97%
EBIT Growth (5y)
-23.72%
EBIT to Interest (avg)
51.75
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.71
Sales to Capital Employed (avg)
0.54
Tax Ratio
12.41%
Dividend Payout Ratio
69.48%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
13.28%
ROE (avg)
7.19%
Valuation key factors
Factor
Value
P/E Ratio
98
Industry P/E
Price to Book Value
6.16
EV to EBIT
98.39
EV to EBITDA
59.93
EV to Capital Employed
20.79
EV to Sales
9.27
PEG Ratio
0.14
Dividend Yield
0.58%
ROCE (Latest)
21.13%
ROE (Latest)
6.30%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
490.70
500.50
-1.96%
Operating Profit (PBDIT) excl Other Income
115.70
71.00
62.96%
Interest
0.30
0.30
Exceptional Items
3.40
4.40
-22.73%
Consolidate Net Profit
96.40
51.00
89.02%
Operating Profit Margin (Excl OI)
169.90%
77.30%
9.26%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -1.96% vs 29.56% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 89.02% vs 171.28% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,752.80
1,424.70
23.03%
Operating Profit (PBDIT) excl Other Income
185.00
-206.30
189.68%
Interest
3.00
3.10
-3.23%
Exceptional Items
12.70
12.50
1.60%
Consolidate Net Profit
128.50
-207.50
161.93%
Operating Profit Margin (Excl OI)
53.00%
-206.10%
25.91%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 23.03% vs -22.89% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 161.93% vs 22.05% in Dec 2023
About Beijing Aosaikang Pharmaceutical Co., Ltd. 
Beijing Aosaikang Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






